ATE281649T1 - Nachweis und bestimmung von stufen der coronaren arterienerkrankung - Google Patents

Nachweis und bestimmung von stufen der coronaren arterienerkrankung

Info

Publication number
ATE281649T1
ATE281649T1 AT99944731T AT99944731T ATE281649T1 AT E281649 T1 ATE281649 T1 AT E281649T1 AT 99944731 T AT99944731 T AT 99944731T AT 99944731 T AT99944731 T AT 99944731T AT E281649 T1 ATE281649 T1 AT E281649T1
Authority
AT
Austria
Prior art keywords
sample
clinically significant
patient
marker
testing
Prior art date
Application number
AT99944731T
Other languages
English (en)
Inventor
Paul N Holvoet
Desire J Collen
Original Assignee
Leuven Res & Dev V Z W
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leuven Res & Dev V Z W filed Critical Leuven Res & Dev V Z W
Application granted granted Critical
Publication of ATE281649T1 publication Critical patent/ATE281649T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/973—Simultaneous determination of more than one analyte
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/809—Multifield plates or multicontainer arrays
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/819—Multifunctional antigen or antibody
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/104165—Lipid, cholesterol, or triglyceride standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99944731T 1998-09-04 1999-08-31 Nachweis und bestimmung von stufen der coronaren arterienerkrankung ATE281649T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/148,158 US6309888B1 (en) 1998-09-04 1998-09-04 Detection and determination of the stages of coronary artery disease
PCT/IB1999/001596 WO2000014548A1 (en) 1998-09-04 1999-08-31 Detection and determination of the stages of coronary artery disease

Publications (1)

Publication Number Publication Date
ATE281649T1 true ATE281649T1 (de) 2004-11-15

Family

ID=22524551

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99944731T ATE281649T1 (de) 1998-09-04 1999-08-31 Nachweis und bestimmung von stufen der coronaren arterienerkrankung

Country Status (8)

Country Link
US (4) US6309888B1 (de)
EP (2) EP1503213A3 (de)
AT (1) ATE281649T1 (de)
AU (1) AU5754699A (de)
CA (1) CA2342365C (de)
DE (1) DE69921668T2 (de)
ES (1) ES2228098T3 (de)
WO (1) WO2000014548A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US20030077668A1 (en) * 1999-07-22 2003-04-24 Ikagaku Co., Ltd. Method for arteriosclerosis diagnosis
GB0001089D0 (en) * 2000-01-18 2000-03-08 Council Cent Lab Res Councils Lipoprotein assay
WO2001063299A1 (en) * 2000-02-23 2001-08-30 Besst-Test Aps METHOD FOR CORRELATING BLOOD COAGULATION ACTIVITY WITH MARKERS IN BODY FLUIDS, e.g. URINE
US6596544B1 (en) * 2000-03-31 2003-07-22 The Regents Of The University Of California Functional assay of high-density lipoprotein
US7250304B2 (en) * 2000-03-31 2007-07-31 The Regents Of The University Of California Functional assay of high-density lipoprotein
GB0027309D0 (en) * 2000-11-08 2000-12-27 Barts And The London Nat Healt Method of measuring measuring platlet activation
IL156015A0 (en) 2000-11-24 2003-12-23 Vascular Biogenics Ltd Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
BE1013881A6 (fr) * 2000-12-21 2002-11-05 Univ Bruxelles Fractions de ldl oxydees, procede d'obtention et utilisation a but diagnostique ou therapeutique.
US20040176914A1 (en) * 2001-04-13 2004-09-09 Biosite Incorporated Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20030199000A1 (en) * 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040126767A1 (en) * 2002-12-27 2004-07-01 Biosite Incorporated Method and system for disease detection using marker combinations
US20030219734A1 (en) * 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040121350A1 (en) * 2002-12-24 2004-06-24 Biosite Incorporated System and method for identifying a panel of indicators
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US7524635B2 (en) * 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US20050130321A1 (en) * 2001-04-23 2005-06-16 Nicholson Jeremy K. Methods for analysis of spectral data and their applications
EP1322957B1 (de) * 2001-05-04 2009-08-12 Biosite Incorporated Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
US7608406B2 (en) * 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
DE60233949D1 (de) * 2001-08-20 2009-11-19 Biosite Inc Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
US20040209307A1 (en) * 2001-08-20 2004-10-21 Biosite Incorporated Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040219509A1 (en) * 2001-08-20 2004-11-04 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7476551B2 (en) * 2001-08-27 2009-01-13 The Board Of Trustees Of The University Of Arkansas Diagnosing atherosclerosis risk by measuring carbamylated low density lipoprotein levels
ES2375181T3 (es) 2002-05-09 2012-02-27 The Brigham And Women's Hospital, Inc. 1l 1rl-1 como un marcador de enfermedades cardiovasculares.
NZ539734A (en) * 2002-10-09 2011-07-29 Dmi Biosciences Inc Diagnosis and monitoring of inflammation, ischemia and appendicitis
WO2005038912A1 (en) * 2002-10-11 2005-04-28 Chien-Min Sung Carbonaceous heat spreader and associated methods
DE602004022150D1 (de) * 2003-03-27 2009-09-03 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
US7095245B2 (en) * 2003-11-14 2006-08-22 Intel Corporation Internal voltage reference for memory interface
WO2005064307A2 (en) * 2003-12-23 2005-07-14 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring anti-ccp and interleukin 6
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
FR2876453B1 (fr) * 2004-10-11 2007-01-12 Biomerieux Sa Procede de diagnostic d'exclusion in vitro des syndromes coronariens aigus
DK1831699T3 (da) * 2004-12-20 2010-03-15 Antibodyshop As Bestemmelse af neutrofil gelatine-associeret lipocalin (NGAL) som en diagnostisk markør for nyresygdomme
WO2006094185A2 (en) * 2005-03-03 2006-09-08 Dmi Biosciences Inc. Quantification of proteins
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
EP1874334A4 (de) * 2005-04-15 2011-03-30 Vascular Biogenics Ltd Zusammensetzungen mit von beta 2-glykoprotein i stammenden peptiden zur prävention und/oder behandlung von gefässerkrankungen
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
PL2035835T3 (pl) 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
US7972794B2 (en) * 2006-07-18 2011-07-05 Quest Diagnostics Investments Incorporated Oxidized apoA-I determination by mass spectrometry
WO2008017306A1 (en) * 2006-08-07 2008-02-14 Antibodyshop A/S Diagnostic test to exclude significant renal injury
US20080050749A1 (en) * 2006-08-17 2008-02-28 Ildiko Amann-Zalan Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
US7776605B2 (en) * 2006-10-26 2010-08-17 Abbott Laboratories Assay for cardiac troponin autoantibodies
US20080305512A1 (en) * 2006-10-26 2008-12-11 Mattingly Phillip G Assay for cardiac troponin autoantibodies
EP2097750A2 (de) * 2006-10-26 2009-09-09 Abbott Laboratories Immunoassay aus analyten in proben mit endogenen antikörpern gegen analyte
MX2009006744A (es) * 2006-12-22 2009-06-30 Abbott Lab Panel de padecimiento cardiovascular autoinmune y metodos de utilizacion del mismo.
EP2137538B1 (de) * 2007-03-21 2014-04-09 Bioporto Diagnostics A/s Diagnostischer test auf nierenverletzung
US7521248B2 (en) * 2007-04-20 2009-04-21 Atherotech, Inc. Apo B measurement system and method
EP2215481B2 (de) * 2007-11-15 2017-01-18 Bioporto Diagnostics A/S Diagnostische verwendung individueller molekularer formen eines biomarkers
US8796184B2 (en) 2008-03-28 2014-08-05 Sentilus, Inc. Detection assay devices and methods of making and using the same
PT3093663T (pt) 2008-04-18 2018-10-19 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
US20090327335A1 (en) * 2008-06-30 2009-12-31 General Electric Company Systems and Methods For Generating Vendor-Independent Computer-Aided Diagnosis Markers
WO2010009269A2 (en) * 2008-07-15 2010-01-21 Piedmont Healthcare, Inc. Method for coronary artery disease risk assessment
EP2319924B1 (de) * 2008-08-15 2016-03-09 Fujikura Kasei Co., Ltd. Polypeptidmarker zur diagnose von arteriosklerose, verfahren für den nachweis von arteriosklerose anhand des markers oder dergleichen und kit für die diagnose von arteriosklerose
CN104634955B (zh) 2009-10-26 2016-09-14 雀巢产品技术援助有限公司 检测抗-tnf药物和自身抗体的试验
EP2568294B1 (de) * 2009-11-13 2015-01-07 BG Medicine, Inc. Risikofaktoren Und Vorhersage Von Myokardinfarkt
WO2011125877A1 (ja) * 2010-03-31 2011-10-13 積水メディカル株式会社 イムノクロマトグラフィーを利用した測定方法、イムノクロマトグラフィー用テストストリップ及びイムノクロマトグラフィー用測定試薬キット
WO2011151783A1 (en) * 2010-05-31 2011-12-08 University Hospital Of Basel Method for assaying lower respiratory tract infection or inflammation
WO2012054532A1 (en) 2010-10-18 2012-04-26 Prometheus Laboratories Inc. Methods for determining anti-drug antibody isotypes
WO2013006810A1 (en) 2011-07-06 2013-01-10 Nestec Sa Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
CA2847839A1 (en) * 2011-09-07 2013-03-14 Genway Biotech, Inc. Diagnostic assay to predict cardiovascular risk
EP2761301A1 (de) * 2011-09-26 2014-08-06 Université Pierre et Marie Curie (Paris 6) Verfahren zur bestimmung einer prädiktiven funktion zur unterscheidung von patienten nach ihrem krankheitsaktivitätsstatus
US20130295685A1 (en) * 2012-04-10 2013-11-07 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies
CN102680710B (zh) * 2012-05-22 2014-06-11 成都华神生物技术有限责任公司 一种人氧化低密度脂蛋白的酶联免疫检测试剂盒及使用方法、用途
IN2015DN01767A (de) 2012-08-21 2015-05-29 Critical Care Diagnostics Inc
EP2730923A1 (de) * 2012-11-09 2014-05-14 Roche Diagniostics GmbH NTproBNP- und cTnT-basierte Therapieanleitung bei Herzversagen
US20150260631A1 (en) * 2014-03-17 2015-09-17 Health Diagnostic Laboratory, Inc. System and method for assessing quanitites or sizes of lipoprotein particles from lipoprotein particle compositions
RU2017122720A (ru) 2014-12-05 2019-01-10 Нестек С.А. Непрямые однородные анализы по изменению подвижности для детекции биологических препаратов в образцах пациента
CN104914255A (zh) * 2015-05-21 2015-09-16 北京协和洛克生物技术有限责任公司 一种检测样本中氧化低密度脂蛋白浓度的试剂盒及其制备方法
EP3440467B1 (de) * 2016-04-08 2020-05-13 Lunginnov Verfahren zur diagnose von postoperativen lungenentzündungen bei patienten nach einer operation
WO2017210360A1 (en) 2016-05-31 2017-12-07 Cardiovax, Llc Methods for diagnosing and treating systemic lupus erythematosus
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
TW202342982A (zh) * 2021-12-28 2023-11-01 美商阿克松根股份有限公司 用於偵測組織內層連結蛋白β-1次單元之系統及方法
CA3244626A1 (en) * 2021-12-31 2023-07-06 Baxter International, Inc. DETERMINATION OF OXIDATING SUBSTANCES BY PEPTIDE DEGRADATION
CN114533264A (zh) * 2022-01-25 2022-05-27 中山大学孙逸仙纪念医院 一种无症状性冠脉疾病的预测模型训练方法、装置及系统
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
ATE121197T1 (de) 1988-01-19 1995-04-15 Pasteur Institut Immunometrisches verfahren zum nachweis von lipoprotein-teilchen, anti-lp(a) monoklonale antikörper und ihre anwendung zur diagnose von atherosklerose.
US5120834A (en) 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
US5453359A (en) 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5223410A (en) 1988-06-13 1993-06-29 American Biogenetic Sciences, Inc. Method for production of antibodies utilizing an antigen-free animal
US5046499A (en) 1988-06-13 1991-09-10 Centocor, Inc. Method for myocardial infarct risk assessment
US5024829A (en) 1988-11-21 1991-06-18 Centocor, Inc. Method of imaging coronary thrombi
US5026537A (en) 1989-04-06 1991-06-25 Centocor, Inc. Methods for imaging atherosclerotic plaque
US5196324A (en) 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
US5604105B1 (en) * 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
US5710008B1 (en) * 1990-10-12 1999-09-07 Spectral Diagnostics Inc Method and device for diagnosing and distinguishing chest pain in early onset thereof
JP3115587B2 (ja) 1990-11-07 2000-12-11 第一化学薬品株式会社 モノクローナル抗体及びマロンジアルデヒド化低比重リポタンパクの測定法
EP0590200A1 (de) 1992-10-02 1994-04-06 E.R. SQUIBB & SONS, INC. Gerät und Verfahren zur Sichtbarmachung von kardiovaskulären Risikofaktoren
US5380667A (en) 1992-10-30 1995-01-10 The United States Of America As Represented By The Secretary Of The Air Force Serum bilirubin and liver function tests as risk predictors for coronary artery disease
US5362649A (en) 1993-02-16 1994-11-08 The United States Of America As Represented By The Secretary Of The Air Force Method for concentration based analysis of lipid fatty acids and its use in determining the likelihood that a patient is at risk for coronary artery disease
WO1994023302A1 (en) 1993-04-07 1994-10-13 The Australian National University Immunological assay of oxidatively modified human low density lipoproteins in plasma
EP0728019A4 (de) 1993-11-08 1999-07-07 Peptide Delivery Systems Pty L Maskierte diagnostikpräparate und verfahren für ihre verwendung
US5487892A (en) 1994-02-24 1996-01-30 American Biogenetic Sciences, Inc. Method for treating thrombotic disease using a fibrin specific monoclonal antibody
US5658729A (en) 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis
JPH095323A (ja) 1995-04-21 1997-01-10 Wako Pure Chem Ind Ltd 酸化低比重リポ蛋白質の測定方法
JP3365885B2 (ja) 1995-04-28 2003-01-14 株式会社ベッセルリサーチ・ラボラトリー ヒト酸化リポタンパク質の測定法
US5690103A (en) 1996-06-20 1997-11-25 Groth; Torgny Lars Detection/exclusion of acute myocardial infarction using neural network analysis of measurements of biochemical markers
US5731208A (en) 1996-09-09 1998-03-24 Washington University Method of detecting conditions indicative of atherosclerosis
WO1998043630A1 (en) * 1997-04-02 1998-10-08 Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
CA2294355C (en) 1997-06-20 2006-11-28 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and mda-modified low density lipoproteins
US6727102B1 (en) * 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
ES2375268T3 (es) * 2000-12-14 2012-02-28 The Brigham And Women's Hospital, Inc. Marcadores inflamatorios para la detección y prevención de diabetes mellitus.
JP2005515407A (ja) * 2001-11-05 2005-05-26 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド アテローム硬化症の予後マーカーとしての可溶性ｃｄ４０ｌ（ｃｄ１５４）

Also Published As

Publication number Publication date
ES2228098T3 (es) 2005-04-01
US7166469B2 (en) 2007-01-23
US20070190586A1 (en) 2007-08-16
DE69921668T2 (de) 2005-12-01
EP1110092A1 (de) 2001-06-27
CA2342365A1 (en) 2000-03-16
EP1503213A3 (de) 2005-07-13
US7604952B2 (en) 2009-10-20
DE69921668D1 (de) 2004-12-09
US20030013127A1 (en) 2003-01-16
US6309888B1 (en) 2001-10-30
AU5754699A (en) 2000-03-27
WO2000014548A1 (en) 2000-03-16
EP1110092B1 (de) 2004-11-03
EP1503213A2 (de) 2005-02-02
CA2342365C (en) 2008-05-06
US20010049112A1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
DE69921668D1 (de) Nachweis und bestimmung von stufen der coronaren arterienerkrankung
Bruinstroop et al. Elevated D‐dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta‐analysis
ATE546734T1 (de) Risikomarker für eine herzkreislaufkrankheit
ATE376187T1 (de) Nachweis von erkrankungen der nieren und behandlung
NO994365L (no) Forutsigelse av koronararterie-sykdom
ATE363655T1 (de) Vorrichtungen und methoden zur bestimmung von konzentrationen von analyten
ATE394658T1 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
DE60138829D1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
EP1221620A3 (de) Verfahren zum Ausführen einer Bestimmung der "activated clotting time" mit geringer Empfindlichkeit gegenüber die Anwesenheit des Aprotinins sowie zur Ermittlung der Aprotinin-Empfindlichkeit
DE60026287D1 (de) Nmr-verfahren zur bestimmung des risikos zur entwicklung von diabetes type 2
MY133942A (en) Reagent test strip for analyte determination having hemolyzing agent
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
ATE197964T1 (de) Bestimmung von mutationen im zusammenhang mit dem digeorge-syndrom
Katzel et al. Risk factors for exercise-induced silent myocardial ischemia in healthy volunteers
NO953770L (no) Analysemetode
DE60133510D1 (de) Automatisches Verfahren zur quantitativen Bestimmung und Überwachung von exogenem Hämoglobin in Vollblut, Blutplasma und Blutserum
ATE395433T1 (de) Screeningverfahren für geeignete wirkstoffe
ATE126599T1 (de) Verfahren zur bestimmung von anti-rns- antikörpern.
WO2000026251A3 (en) A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
AU6679501A (en) A method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality
ATE159102T1 (de) Serum antioxydationsmittel zur voraussage von adult respiratory distress syndrome
DE59808639D1 (de) Verfahren zur bestimmung von schilddrüsen-autoantikörpern
ATE261120T1 (de) Anhand der konduktivität normalisierte bestimmung von analyten in urin zur diagnose von krankheiten
RU98113547A (ru) Способ оценки степени тяжести синдрома мальабсорбции у детей
IL143639A0 (en) Method for determining the activity of a substance using a functional test in vitro

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties